Lecanemab Set A New Bar In Alzheimer’s, Now Many Drugs Are Seeking To Raise It
Executive Summary
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
You may also be interested in...
Lilly’s Donanemab, Now At FDA, Poised To Join Alzheimer’s Armamentarium
Lilly expects US approval of the anti-amyloid therapy by the end of the year. Full Phase III data were detailed at AAIC.
CMS Approval Will Mark ‘Starting Gate’ For Leqembi Launch For Biogen
Biogen will likely add sales reps to support Eisai’s US commercial launch of the Alzheimer’s drug early next year when treatment capacity increases.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.